MYB87 Antibody

What is the MYB87 antibody and what is its target?

MYB87 is a monoclonal antibody with high specificity for Mycoplasma bovis strain M23 and several other M. bovis strains (including Emm, Bat, 1315, M66, and M84). It is mouse-derived and primarily used in ELISA applications for detecting M. bovis in research settings . This antibody should not be confused with antibodies targeting the MYB transcription factor (c-Myb), which is involved in hematopoietic cell development and leukemia .

What are the primary applications for MYB87 antibody?

The primary validated application for MYB87 antibody is ELISA (Enzyme-Linked Immunosorbent Assay). It has been specifically designed and validated for the detection of Mycoplasma bovis in microbiology research contexts . While not directly stated in the available data, this suggests the antibody is valuable for diagnostic research, pathogen detection studies, and investigations into M. bovis infections.

What is the recommended storage protocol for MYB87 antibody?

Based on standard protocols for similar research antibodies, MYB87 should be stored according to manufacturer recommendations. For most antibodies in liquid form, storage at -20°C is typically recommended to maintain stability and reactivity . The antibody preparation contains preservatives (likely sodium azide) and may be shipped on dry ice to maintain integrity . Always refer to the specific product documentation for definitive storage instructions.

How should MYB87 antibody be validated before experimental use?

Before incorporating MYB87 antibody into research protocols, validation should include:

• Positive control testing using known M. bovis strains (particularly strain M23)

• Negative control testing with non-M. bovis mycoplasma species

• Concentration optimization through titration experiments

• Specificity assessment against the six recognized strains (M23, Emm, Bat, 1315, M66, M84)

• Use of appropriate isotype controls (IgM kappa is recommended)

How does MYB87 antibody compare with other antibodies for mycoplasma detection?

While direct comparative studies are not provided in the available data, researchers should consider several factors when comparing MYB87 to other mycoplasma detection antibodies:

When selecting between antibodies, researchers should prioritize specificity requirements based on experimental goals. MYB87's high strain specificity makes it particularly valuable for targeted M. bovis detection .

What are the potential cross-reactivity concerns when using MYB87 antibody?

Though MYB87 demonstrates high specificity for the six identified M. bovis strains, researchers should be aware of potential cross-reactivity issues:

• Consider testing against closely related Mycoplasma species to confirm specificity

• Evaluate potential cross-reactivity with host proteins in complex biological samples

• Perform pre-absorption controls if working with samples containing multiple Mycoplasma species

• Be aware that the antibody's specificity may not extend to newly identified or genetically divergent M. bovis strains

When designing experiments, include appropriate controls to account for these potential cross-reactivity issues .

What are the recommended troubleshooting strategies for inconsistent MYB87 antibody performance in ELISA?

When encountering variable or suboptimal results with MYB87 in ELISA applications, consider these methodological adjustments:

• Antibody concentration optimization:

  • Perform a titration series (typically 0.1-1.0 μg/ml for primary antibody)

  • Test different blocking agents (BSA, casein, or commercial blocking buffers)

• Sample preparation refinement:

  • Ensure proper lysis of mycoplasma cells before assay

  • Filter samples to remove potential interfering components

  • Consider pre-clearing samples if background is high

• Protocol modifications:

  • Adjust incubation times and temperatures

  • Optimize washing steps (frequency and buffer composition)

  • Test different detection systems (HRP vs. AP conjugates)

• Quality control checks:

  • Verify antibody integrity (avoid repeated freeze-thaw cycles)

  • Ensure buffers are freshly prepared and at correct pH

  • Include reference standards on each plate for normalization

How can MYB87 antibody be integrated into multiplex detection systems for comprehensive mycoplasma screening?

For researchers developing comprehensive mycoplasma detection protocols, MYB87 can be integrated into multiplex systems through several approaches:

• Bead-based multiplex assays:

  • Conjugate MYB87 to uniquely identifiable beads

  • Combine with other mycoplasma-specific antibodies on different bead sets

  • Analyze using flow cytometry or dedicated multiplex readers

• Microarray applications:

  • Immobilize MYB87 in specific positions on antibody arrays

  • Create comprehensive mycoplasma detection arrays with multiple antibodies

  • Develop standardized signal quantification protocols

• Sequential ELISA strategies:

  • Design workflow where positive samples from broad-spectrum assays are tested with MYB87

  • Develop algorithmic approaches to interpret results across multiple antibodies

• Complementary molecular methods:

  • Use in parallel with PCR-based detection

  • Correlate antibody reactivity with genetic markers

  • Create integrated detection protocols combining immunological and molecular techniques

What controls should be included when using MYB87 antibody in research protocols?

A robust experimental design using MYB87 antibody should include these essential controls:

• Positive controls:

  • Known M. bovis strain M23 samples

  • Previously validated positive specimens

  • Recombinant M. bovis antigens (if available)

• Negative controls:

  • Closely related non-M. bovis Mycoplasma species

  • Samples from uninfected sources

  • Buffer-only controls

• Antibody controls:

  • IgM kappa isotype control (recommended specifically for MYB87)

  • Secondary antibody-only controls

  • Pre-immune serum controls (when appropriate)

• Technical controls:

  • Replicate samples to assess reproducibility

  • Standard curves for quantitative applications

  • Inter-assay calibrators for longitudinal studies

Proper implementation of these controls ensures reliable interpretation of results and aids in troubleshooting when unexpected results occur.

How should researchers optimize ELISA protocols specifically for MYB87 antibody?

Optimizing ELISA protocols for MYB87 requires systematic assessment of multiple parameters:

• Coating conditions:

  • Test different coating buffers (carbonate/bicarbonate, PBS)

  • Optimize antigen concentration (typically 1-10 μg/ml)

  • Compare overnight 4°C versus shorter higher-temperature coating

• Blocking parameters:

  • Evaluate different blocking agents (BSA, milk proteins, commercial blockers)

  • Test blocking times (1-3 hours) and temperatures (RT vs. 37°C)

• Antibody parameters:

  • Titrate MYB87 concentration (starting with manufacturer recommendations)

  • Optimize incubation time and temperature

  • Test different diluents to reduce background

• Detection system:

  • Compare direct vs. indirect detection approaches

  • Optimize secondary antibody concentration

  • Evaluate substrate development times

• Data analysis:

  • Establish appropriate cutoff values using ROC analysis

  • Implement standardized calculation methods for quantitative results

  • Develop normalization strategies for plate-to-plate comparison

What are the considerations for using MYB87 in research involving clinical or field samples?

When applying MYB87 antibody to clinical or field samples, researchers should address these methodological considerations:

• Sample preparation:

  • Develop standardized collection protocols to ensure consistency

  • Optimize sample processing methods for different sample types (serum, tissue, milk, etc.)

  • Establish appropriate storage conditions to maintain sample integrity

• Interference mitigation:

  • Implement pre-clearing steps to remove potential interfering substances

  • Test for matrix effects by spiking known quantities of target into different sample types

  • Develop sample-specific dilution protocols to minimize background

• Validation requirements:

  • Establish analytical sensitivity and specificity for each sample type

  • Determine limits of detection in complex matrices

  • Compare with reference methods (culture, PCR) for method agreement

• Data interpretation:

  • Develop sample-specific cutoff values

  • Account for endemic exposure in control populations

  • Consider the impact of treatment or vaccination on antibody detection

How can researchers increase the sensitivity of mycoplasma detection using MYB87 antibody?

To enhance detection sensitivity when using MYB87 antibody, researchers can implement these methodological approaches:

• Sample enrichment techniques:

  • Concentration of target organisms through centrifugation

  • Selective culture enrichment before testing

  • Immunomagnetic separation to isolate target organisms

• Signal amplification strategies:

  • Employ polymeric detection systems (e.g., poly-HRP conjugates)

  • Implement tyramide signal amplification (TSA)

  • Utilize biotin-streptavidin systems for enhanced signal

• Detection technology enhancements:

  • Consider chemiluminescent substrates for greater sensitivity

  • Employ fluorescence-based detection systems

  • Investigate electrochemiluminescence platforms

• Protocol modifications:

  • Extend sample incubation times at optimized temperatures

  • Use orbital shakers during incubations to enhance binding kinetics

  • Implement more stringent washing procedures to reduce background

These approaches can be systematically tested and combined to achieve optimal sensitivity for specific research applications.

How does the performance of MYB87 compare in different sample matrices?

The performance of MYB87 antibody may vary considerably across different biological matrices:

Researchers should validate the antibody performance in their specific sample types and develop matrix-specific protocols as needed.

What approaches can be used to quantify M. bovis using MYB87 antibody?

For quantitative applications using MYB87 antibody, researchers should consider these methodological approaches:

• Standard curve development:

  • Prepare purified M. bovis at known concentrations

  • Create log-dilution series covering expected range

  • Include standards on each plate to account for inter-assay variation

• Quantification methods:

  • Implement four-parameter logistic curve fitting

  • Establish linear range of detection

  • Determine lower limit of quantification (LLOQ)

• Standardization strategies:

  • Develop reference materials with assigned values

  • Implement internal controls for normalization

  • Consider international standard alignment where available

• Validation parameters:

  • Assess precision (intra and inter-assay CV%)

  • Determine accuracy through spike-recovery experiments

  • Evaluate linearity across the measuring range

Proper quantification requires rigorous method validation and consistent application of standardized protocols.

How can MYB87 antibody be used in epidemiological studies of M. bovis?

MYB87 antibody offers valuable applications in epidemiological research on M. bovis:

• Prevalence studies:

  • Screening of population samples to determine infection rates

  • Tracking changes in prevalence over time

  • Comparing M. bovis distribution across different geographical regions

• Outbreak investigation:

  • Rapid screening of multiple samples during suspected outbreaks

  • Confirmation of index cases

  • Tracking the spread through susceptible populations

• Strain distribution analysis:

  • Identifying the prevalence of specific strains (M23, Emm, Bat, 1315, M66, M84)

  • Correlating strain types with clinical outcomes

  • Monitoring strain evolution over time

• Risk factor assessment:

  • Testing environmental samples to identify reservoirs

  • Evaluating transmission pathways

  • Assessing intervention effectiveness

Researchers should develop standardized testing protocols to ensure data comparability across sites and studies.

What are the limitations of using MYB87 antibody in research applications?

Researchers should be aware of these important limitations when using MYB87 antibody:

• Specificity constraints:

  • Limited to detection of specific M. bovis strains (M23, Emm, Bat, 1315, M66, M84)

  • May not detect novel or genetically divergent strains

  • Not suitable for pan-mycoplasma detection

• Technical limitations:

  • Primary validation only in ELISA format

  • May require optimization for use in other immunoassay formats

  • Performance in complex biological matrices requires validation

• Biological factors:

  • Cannot distinguish between viable and non-viable organisms

  • Detection may be affected by stage of infection

  • Host antibody responses may interfere with direct detection assays

• Analytical considerations:

  • Semi-quantitative rather than absolutely quantitative without extensive validation

  • May show batch-to-batch variation requiring regular calibration

  • Limited by the inherent sensitivity of the immunoassay format used

Understanding these limitations is essential for proper experimental design and accurate interpretation of results.